185 related articles for article (PubMed ID: 34972751)
41. Immunohistological Expression of SOX-10 in Triple-Negative Breast Cancer: A Descriptive Analysis of 113 Samples.
Kriegsmann K; Flechtenmacher C; Heil J; Kriegsmann J; Mechtersheimer G; Aulmann S; Weichert W; Sinn HP; Kriegsmann M
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899175
[TBL] [Abstract][Full Text] [Related]
42. Expression of SOX10 in Triple-Negative Breast Carcinoma in Pakistan.
Ali S; Rathore Z; Rafique Z; Chughtai AS; Atiq A
Cureus; 2022 Aug; 14(8):e27938. PubMed ID: 36120242
[TBL] [Abstract][Full Text] [Related]
43. Comparative clinicopathological and cytomorphological analyses of peritoneal carcinomatosis associated with metastatic breast carcinoma and primary peritoneal/ovarian carcinoma in patients with a history of breast carcinoma.
Na K; Lee JY; Sung JY; Kim GM; Koo JS; Kim HS
Virchows Arch; 2018 Aug; 473(2):165-175. PubMed ID: 29926183
[TBL] [Abstract][Full Text] [Related]
44. Utility of different immunostains for diagnosis of metastatic breast carcinomas in both surgical and cytological specimens.
Hou Y; Shen R; Chaudhary S; Tonkovich D; Li Z
Ann Diagn Pathol; 2017 Oct; 30():21-27. PubMed ID: 28965624
[TBL] [Abstract][Full Text] [Related]
45. Use of PAX8 and GATA3 in diagnosing sarcomatoid renal cell carcinoma and sarcomatoid urothelial carcinoma.
Chang A; Brimo F; Montgomery EA; Epstein JI
Hum Pathol; 2013 Aug; 44(8):1563-8. PubMed ID: 23453625
[TBL] [Abstract][Full Text] [Related]
46. PAX8 Expression in Breast Cancer.
Lu S; Yakirevich E; Hart J; Wang L; Wang Y
Appl Immunohistochem Mol Morphol; 2021 Apr; 29(4):293-298. PubMed ID: 33208672
[TBL] [Abstract][Full Text] [Related]
47. Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls.
Cimino-Mathews A
Mod Pathol; 2021 Jan; 34(Suppl 1):62-77. PubMed ID: 33110239
[TBL] [Abstract][Full Text] [Related]
48. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.
Cimino-Mathews A; Subhawong AP; Illei PB; Sharma R; Halushka MK; Vang R; Fetting JH; Park BH; Argani P
Hum Pathol; 2013 Jul; 44(7):1341-9. PubMed ID: 23375642
[TBL] [Abstract][Full Text] [Related]
49. Immunohistochemical Characterization of a Large Cohort of Triple Negative Breast Cancer.
Han R; Nofech-Mozes S; Boles D; Wu H; Curcin N; Slodkowska E
Int J Surg Pathol; 2024 Apr; 32(2):239-251. PubMed ID: 37306115
[No Abstract] [Full Text] [Related]
50. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
Ni YB; Tsang JYS; Shao MM; Chan SK; Cheung SY; Tong J; To KF; Tse GM
Breast Cancer Res Treat; 2018 May; 169(1):25-32. PubMed ID: 29340880
[TBL] [Abstract][Full Text] [Related]
51. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
Yang Y; Lu S; Zeng W; Xie S; Xiao S
Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
[TBL] [Abstract][Full Text] [Related]
52. The role of GATA3 in the metastasis of triple-negative breast cancer and high-grade serous ovarian cancer.
El-Arabey AA; Abdalla M
Hum Cell; 2022 Jul; 35(4):1298-1300. PubMed ID: 35459984
[No Abstract] [Full Text] [Related]
53. Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas.
Ivanov SV; Panaccione A; Nonaka D; Prasad ML; Boyd KL; Brown B; Guo Y; Sewell A; Yarbrough WG
Br J Cancer; 2013 Jul; 109(2):444-51. PubMed ID: 23799842
[TBL] [Abstract][Full Text] [Related]
54. Trichorhinophalangeal syndrome type 1 (TRPS1) expression in male breast carcinoma.
Law T; Piotrowski MJ; Ning J; Jiang X; Ding Q; Sahin AA
Hum Pathol; 2023 Aug; 138():62-67. PubMed ID: 37331526
[TBL] [Abstract][Full Text] [Related]
55. Differential expression of epithelial–mesenchymal transition and stem cell markers in intrinsic subtypes of breast cancer.
Pomp V; Leo C; Mauracher A; Korol D; Guo W; Varga Z
Breast Cancer Res Treat; 2015 Nov; 154(1):45-55. PubMed ID: 26467042
[TBL] [Abstract][Full Text] [Related]
56. GATA3 as a putative marker of breast cancer metastasis-A retrospective immunohistochemical study.
De Lara S; Parris TZ; Werner Rönnerman E; Helou K; Kovács A
Breast J; 2018 Mar; 24(2):184-188. PubMed ID: 28703335
[TBL] [Abstract][Full Text] [Related]
57. Unexpected PAX8 Immunoreactivity in Metastatic High-grade Breast Cancer.
Kilgore MR; Bosch DE; Adamson KH; Swanson PE; Dintzis SM; Rendi MH
Appl Immunohistochem Mol Morphol; 2019 Oct; 27(9):637-643. PubMed ID: 30358609
[TBL] [Abstract][Full Text] [Related]
58. High-Grade Endometrioid Carcinoma of the Endometrium With a GATA-3-Positive/PAX8-Negative Immunophenotype Metastatic to the Breast: A Potential Diagnostic Pitfall.
Salibay C; Fadare O
Int J Surg Pathol; 2020 Sep; 28(6):631-636. PubMed ID: 32188328
[TBL] [Abstract][Full Text] [Related]
59. GATA3 immunohistochemistry expression in histologic subtypes of primary breast carcinoma and metastatic breast carcinoma cytology.
Deftereos G; Sanguino Ramirez AM; Silverman JF; Krishnamurti U
Am J Surg Pathol; 2015 Sep; 39(9):1282-9. PubMed ID: 26274030
[TBL] [Abstract][Full Text] [Related]
60. Unusual staining of immunohistochemical markers PAX8 and CDX2 in breast carcinoma: a potential diagnostic pitfall.
Shen T; Zhao J; Zhao M; Taggart MW; Ramalingam P; Gong Y; Wu Y; Liu H; Zhang J; Resetkova E; Wang WL; Ding Q; Huo L; Yoon E
Hum Pathol; 2022 Jul; 125():35-47. PubMed ID: 35417734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
